The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Updated results of the phase 1/2 study of TSN1611, a highly selective KRAS G12D inhibitor, in patients with advanced solid tumors.
 
Jian Li
No Relationships to Disclose
 
Siqing Fu
Research Funding - Abbisko (Inst); Antengene (Inst); BeiGene (Inst); BeyondSpring Pharmaceuticals (Inst); Biotheus (Inst); Boehringer Ingelheim (Inst); Clinical and Translational Science Award Grant (CTSA) 1UM1TR0045906 (Inst); Coherent Biopharma (Inst); CPRIT Precision Oncology Decision Support Core (RP150535) (Inst); Crossignal (Inst); CUE Biopharma (Inst); DEKA Biosciences (Inst); Exelis (Inst); Exelis (Inst); Fore Biotherapeutics (Inst); Greenfire Bio (Inst); Hookipa Pharma (Inst); IMV (Inst); Innovent Biologics (Inst); Jazz Pharmaceuticals (Inst); K-Group Beta (Inst); Lantern Pharma (Inst); Lilly (Inst); Lyvgen Biopharma (Inst); MacroGenics (Inst); MediLink Therapeutics (Inst); Millennium (Inst); Nerviano Medical Sciences (Inst); NeuPharma, Inc. (Inst); NextCure (Inst); NIH/NCI (Inst); Ningbo NewBay Medical Technology (Inst); Novartis (Inst); NovoCure (Inst); Nykode Therapeutics (Inst); Parexel International, LLC (Inst); PharmaMar (Inst); Pionyr (Inst); PureTech (Inst); Qurgen Inc. (Inst); Sellas Life Sciences (Inst); Shanghai Huaota Biopharmaceutical (Inst); Soricimed (Inst); SQZ Biotech (Inst); Sumitomo Dainippon Pharma Oncology (Inst); Taiho Oncology (Inst); Tigermed Group (Inst); TransCode Therapeutics, Inc. (Inst); Treadwell Therapeutics (Inst); Turnstone Bio (Inst); Tyligand Bioscience (Inst); Virogin Biotech (Inst)
 
Alex Spira
Leadership - Next Oncology (Inst)
Honoraria - Abbvie; Abbvie; Abbvie; Amgen; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Janssen Oncology; Merck; Novartis; Prelude Therapeutics; Takeda
Consulting or Advisory Role - Amgen; ArriVent Biopharma; AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Black Diamond Therapeutics; Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); crispr therapeutics; Daiichi Sankyo/Astra Zeneca; GlaxoSmithKline; Gritstone Bio; Gritstone Bio; incyte; Janssen Research & Development; Jazz Pharmaceuticals; Lilly; Merck (Inst); Mersana; Mirati Therapeutics; Novartis; Regeneron; Revolution Medicines; Sanofi; Sanofi; Synthekine; Takeda
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); ADC Therapeutics (Inst); Alkermes (Inst); Amgen (Inst); ArriVent Biopharma (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); Janssen Oncology (Inst); LAM Therapeutics; Lilly (Inst); Loxo (Inst); Loxo (Inst); Macrogenics (Inst); Medikine (Inst); MedImmune (Inst); mersana (Inst); nalo therapeutics (Inst); Novartis (Inst); Plexxikon (Inst); Prelude Therapeutics (Inst); Regeneron (Inst); Revolution Medicines (Inst); Revolution Medicines (Inst); Roche (Inst); Rubius Therapeutics (Inst); Scorpion Therapeutics (Inst); Synthekine (Inst); Synthekine (Inst); Takeda (Inst)
 
Shun Lu
Leadership - Innovent BIOLOGICS, INC; Shanghai Fosun; Simcere Zaiming
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; GenomiCare; Hutchison MediPharma; InventisBio Co. Ltd; Menarini; Pfizer; Roche; Simcere; Yuhan; Zai Lab
Speakers' Bureau - AstraZeneca; Hansoh Pharma; Hengrui Therapeutics; Roche
Research Funding - AstraZeneca (Inst); BeiGene (Inst); BMS (Inst); Hansoh (Inst); Hengrui Therapeutics (Inst); Hutchison MediPharma (Inst); Lilly Suzhou Pharmaceutical Co. (Inst); Roche (Inst)
 
Tianshu Liu
No Relationships to Disclose
 
David Sommerhalder
Employment - Texas Oncology
Stock and Other Ownership Interests - Next Oncology; Texas Oncology/US Oncology
Honoraria - Syneos Health
Consulting or Advisory Role - Abbvie; Cartography Biosciences; Nimbus Therapeutics; Revolution Medicines
Research Funding - Abbvie (Inst); Acrivon Therapeutics (Inst); ADC Therapeutics (Inst); Alentis Therapeutics (Inst); Aprea Therapeutics (Inst); Ascentage Pharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Avenzo Therapeutics (Inst); Axion Bio (Inst); Biomea Fusion (Inst); BioNTech SE (Inst); BJ Bioscience (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Compugen (Inst); DAAN Biotherapeutics (Inst); Day One Biopharmaceuticals (Inst); Dewpoint Therapeutics (Inst); Dicerna (Inst); DualityBio (Inst); Erasca, Inc (Inst); Exelixis (Inst); Fate Therapeutics (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Haihe Pharmaceutical (Inst); IconOVir Bio (Inst); IDEAYA Biosciences (Inst); Immuneering (Inst); IMPAC Medical Systems (Inst); Incendia Pharmaceuticals AB (Inst); Incendia Pharmaceuticals AB (Inst); Ipsen (Inst); Kura Oncology (Inst); MediLink (Inst); Mirati Therapeutics (Inst); ModeX Therapeutics (Inst); Monopteros Therapeutics (Inst); Navire (Inst); NGM Biopharmaceuticals (Inst); Nimbus Therapeutics (Inst); Normunity (Inst); Novo Nordisk (Inst); OBI Pharma (Inst); OncoResponse (Inst); Pfizer (Inst); ProteinQure (Inst); Revolution Medicines (Inst); Step Pharma (Inst); Sutro Biopharma (Inst); Symphogen (Inst); Systimmune (Inst); Tachyon Therapeutics (Inst); Teon Therapeutics (Inst); Tyligand Bioscience (Inst); VelaVigo Pharma Co (Inst); Vincera Pharma/Vincerx Pharma (Inst); Vividion Therapeutics (Inst); ZielBio (Inst); Zymeworks (Inst)
 
Ying Yuan
No Relationships to Disclose
 
Haizhou Lou
No Relationships to Disclose
 
Jianhua Shi
No Relationships to Disclose
 
Yongfeng Yu
No Relationships to Disclose
 
Wei Li
No Relationships to Disclose
 
Ting Xu
No Relationships to Disclose
 
Baorong Song
Employment - Tyligand Bioscience
 
Chunlan Dong
Employment - Tyligand Bioscience
 
Shengtang Ma
Employment - Tyligand Bioscience
 
Jing Li
Employment - Tyligand Bioscience
 
Boyu Zhong
Employment - Tyligand Bioscience
 
Tony Zhang
Employment - Tyligand Bioscience
 
Lin Shen
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; MSD; SERVIER; Transcenta Holding Limited
Research Funding - BeiGene (Inst)